By Emily Mullin
Publication Date: 2026-04-24 17:17:00
AlphaFold by Google DeepMind has already revolutionized scientists’ understanding of proteins. Now the platform’s ability to develop safe and effective medicines is being put to the test.
Isomorphic Labs, the UK-based biotech spin-off of Google DeepMind, will soon begin human trials of drugs developed using its Nobel Prize-winning AI technology. “We are preparing to go into the clinic,” Max Jaderberg, president of Isomorphic Labs, said April 16 at WIRED Health in London. “It will be a very exciting moment when we start clinical trials and start to see the effectiveness of these molecules.”
Jaderberg did not provide details on the timeline, but it is later than the company had planned to begin human trials. Last year, CEO Demis Hassabis said it would have AI-developed drugs in clinical trials by the end of 2025.
Isomorphic Labs was founded in 2021 as a spin-off from Alphabet’s AI research subsidiary Google DeepMind. The company uses DeepMind’s AlphaFold, a…
